glp-1 and testosterone Medications Can Increase Levels in Men With Obesity glp-1 and testosterone in women

This understanding bears significant implications in the investigation of conditions like osteoporosis, in which disruptions to these signaling pathways occur

Published in Nature Communications, the study suggests that GLP-1based weight-loss medications could represent a promising new therapeutic strategy for improving recovery after a heart attack

Someone with severe abdominal swelling, significant pain, or repeated vomiting should seek medical guidance rather than simply adding more fiber and assuming the problem is routine constipation

If youre ready to take control of your weight and improve your health, contact us today to schedule a consultation with one of our medical professionals

Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema